A Clinical Trial of P134 Cells in Recurrent Glioblastoma

Inclusion Criteria: 1. Voluntary written informed consent. 2. 18-70 years of age (inclusive), male or female. 3. Recurrent or progressive glioblastoma, histopathologically or molecularly diagnosed consistent with grade 4 glioblastoma (IDH wild-type) (refer to WHO Classification of Central Nervous System Tumors, 5th Edition, 2021). 4. Positive CD44 or CD133 antigen expression in tumor tissue confirmed by IHC, defined as ≥1% of tumor cells showing positive CD44 or CD133 IHC staining, regardless of intensity (applicable only in Phase II dose expansion study). 5. Patient has received prior radiation therapy and/or temozolomide/bevacizumab. 6. The investigator confirmed that the patient was suitable for craniotomy cerebrospinal fluid shunt and accessory (Ommaya reservoir) implantation. Exclusion Criteria: 1. Highly allergic constitution or history of severe allergy, or allergy to related cell products 2. Received an approved or other investigational anticancer therapy within 2 weeks prior to PBMC collection or within 5 half-lives of the agent, whichever is longer, including, but not limited to: chemotherapy, radiation therapy, surgery (except diagnostic surgery), targeted therapy, cell infusion therapy, hormone therapy (except hormone replacement therapy), and traditional Chinese medicine therapy with a clear anticancer indication (traditional Chinese medicine may undergo a 1-week washout period). 3. The adverse reactions caused by previous anti-tumor treatment have not recovered to ≤ Grade 1 as evaluated by NCI CTCAE v5.0 (except alopecia, skin pigmentation, leukoplakia, etc. which are assessed as having no safety risk). 4. Tumor metastasis to the brainstem or spinal cord. 5. Patients with primary immunodeficiency disease, autoimmune diseases requiring medication (such as Crohn 's disease, ulcerative colitis, rheumatoid arthritis, systemic lupus), or previous history of autoimmune diseases of the nervous system (such as multiple sclerosis, Parkinson' s disease).